Glenmark Pharmaceuticals launches TEVIMBRA in India
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. It is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and esophageal squamous cell carcinoma (ESCC) as monotherapy.
This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio. NSCLC is the most common type of lung cancer, representing over 80% of all lung cancer cases. Similarly, ESCC is the most common histological subtype of esophageal cancer in India. TEVIMBRA caters to the needs of this significant patient population by offering a differentiated and proven treatment option for these cancers.
TEVIMBRA is approved and marketed in multiple leading global markets including the United States, European Union, Australia and China. Designed to selectively bind to PD-1 receptors, TEVIMBRA restores T-cell function while minimizing off-target immune suppression and has demonstrated robust efficacy with a favorable safety profile across diverse solid tumor types in multiple pivotal Phase 3 studies and through a comprehensive global clinical development program.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
a day ago
- Hindustan Times
Skip Ozempics: Cardiologist shares 5 natural habits for healthy weight loss
Medicines like Ozempic and Wegovy are becoming increasingly popular for weight loss. But let us not forget that they can have side effects. Dr. Sanjay Bhojraj, one of the top American cardiologists, says you do not need these injections to lose weight. In fact, if you treat your body right, it can help you shed those extra kilos. To lose weight without Ozempic, cardiologists suggest five habits.(Representative Image: Unsplash) In an Instagram post, the doctor talked about five simple habits that can help you lose weight without Ozempics. These steps can help your body produce more of a natural hormone called GLP-1. This hormone helps control hunger. While Ozempic copies this hormone, you can boost it on your own. Dr. Bhojraj has used this plan in his clinic, and many patients have lost up to 13.6 kg (30 pounds) using these steps. 5 natural daily habits to lose weight According to the official website, lagunalongevity, the following 5 habits are recommended by the cardiologist to lose weight instead of Ozempic intake. 1. Add fiber to every meal Fiber helps you feel full. It also keeps your blood sugar steady. It is very important for increasing GLP-1 naturally. Add fiber-rich foods like vegetables, fruits, and whole grains to every meal. 2. Use healthy fats Good fats like olive oil and avocado oil help balance your hormones. These fats give you energy and reduce cravings. 3. Eat protein before carbs Start your meal with protein. This helps control blood sugar and keeps you satisfied. When you feel full, you eat less. 4. Eat early in the day Try to eat your first meal before 9 am. Your body's clock works better with early meals. This helps release more GLP-1 and controls your appetite better. 5. Eat slowly and do not snack Chew slowly and focus on your food. Eating this way helps your body release more GLP-1. Avoid snacking between meals. It gives your body time to rest and reset hunger hormones. ALSO READ: Fitness coach shares 21 food cheat codes for weight loss: 'Chew your food until it becomes liquid, eat on a blue plate' FAQs Q: Can people lose weight naturally without using Ozempic or Wegovy? Yes. By making simple changes to eating habits, people can help their bodies release more GLP-1 on their own. Q: What is GLP-1, and why is it important for weight loss? GLP-1 is a natural hormone that controls hunger and helps you feel full. Medicines like Ozempic copy this hormone. Q: What foods increase GLP-1 naturally? Foods high in fiber, healthy fats, and protein help raise GLP-1 levels. Q: Why should I eat protein before carbs? Eating protein first helps prevent a big rise in blood sugar. It also helps you feel full sooner, so you don't overeat.
Time of India
2 days ago
- Time of India
Top American cardiologist shares 5 easy steps to lose 13 kg weight naturally, without any injection shot
The Five-Point Plan for Natural Weight Loss About Dr. Sanjay Bhojraj As weight-loss medications like Ozempic and Wegovy gain mainstream popularity, concerns about long-term side effects and dependency have also come into focus. In response, one of America's leading cardiologists has outlined a natural, evidence-backed alternative to help individuals lose up to 13.6 kilograms (30 pounds) without relying on injections or synthetic appetite suppressants. Dr. Sanjay Bhojraj, an interventional cardiologist and certified functional medicine practitioner, recently shared his step-by-step method for activating the body's own mechanisms to manage weight and improve overall doctor explained that injectable drugs such as Ozempic work by mimicking GLP-1, a hormone that helps regulate hunger and satiety. However, through strategic changes in diet and lifestyle, the body can be trained to increase its own production of GLP-1 naturally. In an post on Instagram, he outlined key habits that he has used in his functional medicine clinic to help patients lose significant weight while improving their energy, sleep, and mood—without the potential downsides of Bhojraj's approach is rooted in practical, sustainable adjustments rather than restrictive dieting. These five habits form the foundation of his method:Dietary fiber plays a crucial role in promoting satiety and stabilizing blood sugar levels. According to Dr. Bhojraj, fiber is a key nutrient for stimulating GLP-1 naturally, making it a non-negotiable part of every like olive oil and avocado oil not only support hormone balance but also help regulate appetite. These fats work by signaling the body to relax and increase fat metabolism , contributing to sustained energy levels and reduced order in which food is consumed affects how the body processes it. Eating protein first can help flatten the post-meal blood sugar spike and increase feelings of fullness, making it easier to eat less levels are influenced by the body's circadian rhythm. Bhojraj noted that consuming food earlier in the day—especially before 9 a.m.—leads to a higher natural release of GLP-1 compared to eating later in the eating, which involves chewing slowly and being present during meals, has been linked to better GLP-1 activity. In contrast, frequent snacking disrupts digestive rest and hormone regulation, which can impair natural appetite Bhojraj is a board-certified interventional cardiologist and a certified practitioner with The Institute for Functional Medicine. He is also the founder of Well12, a 12-week wellness program focused on evidence-based lifestyle interventions. His clinical approach covers areas such as genomic medicine, lipid testing, and epigenetics.
Mint
3 days ago
- Mint
Lilly and Novo are the kings of weight-loss drugs. The companies coming for their crowns.
Eli Lilly and Danish pharma giant Novo Nordisk are dominating the market for weight-loss drugs. But a number of competitors are hot on their heels. While Lilly and Novo are still the only two companies with approved weight-loss drugs on sale in the U.S., others are coming for a share of the growing sector. Any way you slice it, the market for weight-loss drugs like the so-called GLP-1 medication made by Lilly and Novo is likely to be huge. Morningstar is one of the most optimistic on this potential, seeing a $200 billion market by 2031. Goldman Sachs cut its estimate in April to $95 billion by 2030, down from $130 billion. That is arguably still a very large number and has attracted more companies to the lucrative industry. Both well-established pharma companies as well as smaller, clinical-stage firms are investing heavily to be able to someday compete with Lilly and Novo. Here's a look at some of the contenders: As one of the largest pharmaceutical companies in the U.S., Amgen has pockets deep enough to invest in the booming obesity drug space, and its drug MariTide has shown potential. Its distinct advantage over current jabs is that it would only have to be injected once a month, as opposed to once a week like Lilly's Zepbound and Novo's Wegovy. In a mid-stage trial, patients lost on average about 20% of their body weight after a year on MariTide, roughly on par with rivals, but a surprisingly large number of participants dropped out due to side effects. A late-stage trial is ongoing. Small cap Viking Therapeutics is a clinical-stage biotech and doesn't yet generate revenue. It announced as late as June 25 that it started a late-stage trial of its injectable weight-loss treatment VK2735. VK2735 is a so-called dual GLP-1 and GIP receptor, meaning it targets two different gut hormones to help control blood sugar levels and appetite, thereby helping patients lose unwanted weight. It's also conducting a mid-stage trial for VK2735 in pill form. An early-stage trial showed adults on the highest dosage of the drug lost on average 8.2% of their body weight in four weeks. This Danish up-and-comer has partnered with Roche and privately held Boehringer Ingelheim to develop next-generation weight-loss drugs. Zealand's portfolio includes medicines targeting both GLPs and GIPs receptors (Dapiglutide/Survodutide/ZP6590) as well as a so-called amylin analog (Petrelintide), which works differently from GLP-1s to increase feelings of fullness. There are hopes that amylin could produce fewer side effects than GLP-1 drugs. Structure Therapeutics is a San Francisco-based clinical-stage biotech that is also developing an amylin receptor agonist, ACCG-2671. It expects to start an early-stage trial of the drug by the end of 2025. Preclinical trials have shown significant weight-loss, but also less severe side effects and muscle mass preservation, according to Structure executives. The company also has an oral GLP-1 candidate in the pipeline. The U.K.'s most valuable company by market capitalization AstraZeneca is another Big Pharma player wanting to get into weight-loss drugs with its candidate AZD5004. The treatment is a small molecule oral GLP-1. Type 2 diabetes patients lost 5.8% of their body weight loss after four weeks of taking the daily pill, with mild to modest gastrointestinal side effects. The drug was licensed by AstraZeneca in 2023 from China's Eccogene and is currently in a mid-stage trial. It has two other injectable weight-loss drugs in the pipeline as well. Swiss-listed Roche is developing three different weight-loss drugs, one in partnership with Zealand Pharma. Its portfolio includes both oral and injectable weight-loss medicines, and both single and dual receptor antagonists. Hopes are high, especially for its oral version, but there have been concerns about side effects. Its jab is in a mid-stage trial while its pill is in an early-stage trial. Write to Elsa Ohlen at
